Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Immtech Signs MOU with Beijing Pharmaceutical Group

publication date: Mar 3, 2009

Immtech Pharmaceuticals signed a Memorandum of Understanding (MOU) declaring its interest in developing a strategic alliance with Beijing Pharmaceutical Group Co. Ltd. (BPGC). The MOU also confirms BPGC’s intention to consider a range of collaborative opportunities with Immtech. The alliance would give BPGC rights to develop drugs from Immtech’s library of compounds, which primarily target hepatitis C and malaria. No financial disclosures were made at this early stage. More details...

Stock Symbol: (NYSE Alternext US: IMM)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital